Standard BioTools (NASDAQ:LAB) Director Acquires $540,000.00 in Stock

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L purchased 450,000 shares of the business’s stock in a transaction dated Thursday, November 13th. The stock was bought at an average cost of $1.20 per share, for a total transaction of $540,000.00. Following the purchase, the director owned 62,500,000 shares in the company, valued at $75,000,000. This trade represents a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Monday, November 17th, Casdin Partners Master Fund, L acquired 225,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.22 per share, with a total value of $274,500.00.
• On Friday, November 14th, Casdin Partners Master Fund, L bought 250,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.24 per share, for a total transaction of $310,000.00.
• On Wednesday, November 12th, Casdin Partners Master Fund, L bought 375,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.19 per share, for a total transaction of $446,250.00.
• On Tuesday, November 11th, Casdin Partners Master Fund, L purchased 300,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.20 per share, with a total value of $360,000.00.
• On Monday, November 10th, Casdin Partners Master Fund, L purchased 275,000 shares of Standard BioTools stock. The stock was purchased at an average price of $1.17 per share, for a total transaction of $321,750.00.
• On Friday, November 7th, Casdin Partners Master Fund, L acquired 225,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.12 per share, for a total transaction of $252,000.00.
• On Tuesday, September 9th, Casdin Partners Master Fund, L acquired 100,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.29 per share, with a total value of $129,000.00.
• On Wednesday, September 3rd, Casdin Partners Master Fund, L bought 250,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.27 per share, with a total value of $317,500.00.
• On Tuesday, August 26th, Casdin Partners Master Fund, L purchased 125,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.26 per share, for a total transaction of $157,500.00.
• On Monday, August 25th, Casdin Partners Master Fund, L purchased 200,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.24 per share, with a total value of $248,000.00.

Standard BioTools Trading Up 3.2%

Shares of Standard BioTools stock opened at $1.28 on Thursday. The company has a market capitalization of $492.24 million, a PE ratio of -4.00 and a beta of 1.25. Standard BioTools Inc. has a 12 month low of $0.92 and a 12 month high of $2.25. The stock’s fifty day simple moving average is $1.28 and its 200 day simple moving average is $1.23.

Hedge Funds Weigh In On Standard BioTools

A number of large investors have recently bought and sold shares of the company. Jump Financial LLC acquired a new stake in shares of Standard BioTools in the first quarter valued at approximately $26,000. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its position in Standard BioTools by 115.6% in the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company’s stock valued at $29,000 after purchasing an additional 14,541 shares in the last quarter. CWM LLC grew its position in Standard BioTools by 101.8% in the first quarter. CWM LLC now owns 29,705 shares of the company’s stock valued at $32,000 after purchasing an additional 14,984 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Standard BioTools by 2,989.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 25,021 shares of the company’s stock valued at $33,000 after buying an additional 24,211 shares during the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in Standard BioTools during the 1st quarter worth about $35,000. Institutional investors and hedge funds own 53.74% of the company’s stock.

Wall Street Analysts Forecast Growth

LAB has been the topic of several recent analyst reports. Cowen cut Standard BioTools from a “buy” rating to a “hold” rating in a report on Wednesday, August 13th. TD Cowen cut their price target on shares of Standard BioTools from $1.55 to $1.35 and set a “hold” rating on the stock in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Standard BioTools in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Standard BioTools from a “hold” rating to a “strong sell” rating in a report on Saturday, November 8th. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Standard BioTools currently has a consensus rating of “Reduce” and an average target price of $1.35.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.